The ability of polyriboinosionic acid [poly(rI)].polyribocytidylic acid [poly-(rC)], mismatched analog poly(rI) poly[r(C12Uracil)n], and poly(rI) poly(rC) complexed with poly L-lysine and carboxymethylcellulose [poly(ICLC)] to induce interferon and the comparative toxicity of each in cats were evaluated. Each induced high levels of circulating interferon, although poly(ICLC) injected intravenously at 1 to 4 mg/kg induced up to 10 times more interferon than the other compounds. Each compound was pyrogenic and caused a transient decrease in leukocyte numbers. Poly(rI) . poly(rC) and the mismatched analog caused severe diarrhea and nausea at the highest drug concentrations (1 to 4 mg/kg), but poly(ICLC) did not. Each compound also caused depression and lethargy and impaired coordination.
A wide variety of double-stranded ribonucleic acid molecules of synthetic or natural origin are known to be active antiviral and interferon-inducing agents (2, 3, 16) . One member of this group, polyriboinosinic acid [poly(rI)] *polyribocytidylic acid [poly(rC)] has been widely studied as a potential chemotherapeutic agent. Poly(rI).poly(rC) is an excellent interferon inducer and antiviral agent in many animal species (4, 16) . However, in humans a relatively low therapeutic ratio has been obtained (5) (6) (7) . Toxic manifestations observed in clinical studies after parenteral administration of poly(rI) -poly(rC) have included transient fever, minor liver enzyme changes, and a slight decrease in circulating leukocyte numbers. In laboratory animals toxicity has included fever and changes in liver function, hematopoiesis, and blood clotting (1, 10) .
Two divergent approaches have recently been taken toward the development of more active or less toxic analogs of poly(rI) *poly(rC). Complexing poly(rI) -poly(rC) with poly L-lysine and carboxymethylcellulose [poly(ICLC)] has resulted in a more stable analog based on decreased sensitivity to ribonuclease destruction (13, 14) . When compared with poly(rI) -poly(rC), poly(ICLC) induced much higher levels of interferon in nonhuman primates and effectively protected them against virus infection (9, 12) . In initial clinical trials in cancer patients, poly(ICLC) has effectively induced high levels of circulating interferon (8) .
Proceeding in the opposite direction, analogs of poly(rI) poly(rC) have been developed that are more sensitive to ribonuclease destruction, the theory being that cells need only be exposed to poly(rI) poly(rC) briefly to reach a plateau level of resistance to virus infection, thereby decreasing toxicity (11, 12) . Analogs have been developed in which a uracil molecule has periodically been inserted into the homopolymer C chain (mismatched), making the molecule more sensitive to ribonuclease (11, 12) . Studies in this report were initiated to compare the toxicity and interferon-inducing capability of each of these polynucleotides in cats. Cats were selected since they are very sensitive to the toxicity of poly(rI) -poly(rC) and respond by producing high levels of circulating interferon.
MATERLALS After overnight incubation at 370C, fluid was removed and monolayers were washed once with 2 ml of phosphate-buffered saline. Plates were then infected with 50 plaque-forming units of vesicular stomatitis virus per plate. After 1 h of absorption, 2 ml of plaquing medium was added to each plate. After 36 to 48 h of incubation at 37°C, plates were stained with 0.03% neutral red and plaques were counted. For standardization, an internal reference cat interferon preparation was included with each assay. Interferon titers are expressed as a reciprocal of that dilution which reduced the number of plaques by 50% as compared with virus controls.
RESULTS
Cats were injected intravenously with polynucleotide (three cats per group), and blood samples were collected at 0, 2, 4, 6, 8, 24, and 48 h after drug administration. Both total and differential leukocyte counts were determined, and serum was collected for interferon assay. Body temperatures were recorded at 1 h before, immediately before, and 0.5, 1, 1.5, 2, 3, 4, 6, 9, 24, 48, and 72 h after drug administration. Physical signs and symptoms were monitored throughout, including vomiting, diarrhea, alertness, coordination, etc. Throughout these studies the same 12 cats were used. They were rested at least 2 weeks between each dose of inducer to allow the animal to recover physically as well as to avoid developing a hyporeactive response (15) .
Interferon. The maximum interferon response induced by each concentration of each of the polynucleotides is illustrated in Fig. 1 sponse of cats in each group. Of the inducers evaluated, poly(ICLC) was the most potent at the highest drug concentrations. At doses of from 1 to 4 mg/kg, poly(ICLC) induced up to 50,000 U of interferon per ml of serum compared to 4,000 to 5,000 U of interferon per ml induced by the others. At the lowest concentrations (0.05 mg/kg), the mismatched analog induced the least interferon.
Fever. In previous studies one of the main toxic manifestations observed after injection of polynucleotides has been a pyrogenic response. Therefore, body temperatures were monitored. In general, after an initial pyrogenic response, body temperatures decreased to abnormally low levels followed by a return to normal 24 to 48 h after injection. The results of both parameters are summarized in Fig. 2 studies. Total leukocyte counts in cats receiving each of the polynucleotides are presented in Fig.  3 . This figure presents the mean of each treatment group 6 h after administration of the compound, which was a time when the maximum effect on leukocyte numbers was observed. With each polynucleotide there was a transient decrease in leukocyte numbers. The maximum decrease occurred at 6 h and then rebounded and returned to normal by 12 h. A dose-dependent effect was observed. The lowest dose of 0.05 mg/ kg did not have a significant effect. As the dose of each compound increased, a transient decrease in leukocyte numbers was observed. At 0.1 and 0.5 mg per kg, poly(rI) .poly(rC) caused the greatest decrease in leukocyte numbers. At the higher drug concentrations, however, each of the other polynucleotides also caused a severe decrease. Differential leukocyte counts were also monitored during these studies. The decrease in leukocyte numbers at the low and medium concentrations (up to 1 mg/kg) was chiefly due to a decrease in circulating lymphocyte numbers. In cats receiving 1 to 4 mg of polynucleotide per kg, however, there was also a decrease in circulating polymorphonuclear leukocyte numbers and an increase in nonsegmented neutrophils, which indicated a shift to juvenile cell forms. Cats were monitored for several months after the administration of polynucleotides, and prolonged effect on circulating leukocyte numbers was not observed.
Physical conditions of cats. Of the parameters followed, the physical appearance of cats appeared to be the most revealing indication of compound toxicity as summarized in Table 1 . Physical signs and symptoms monitored included vomiting, diarrhea, and the development of central nervous system depression, which included a loss of coordination, depression, lethargy, and difficulty in walking. Animals that received the highest concentration of poly(rI). profuse diarrhea with the passage of large volumes of mucus lasting through the first 12 to 24 h. Animals developed central nervous system effects from 2 to 4 h after injection, which then persisted with gradual improvement over the next 10 h. However, animals receiving from 2 to 4 mg of each of the polynucleotides per kg were severely affected. They were lethargic and lifeless during the first 24 to 48 h after drug administration, and cats receiving 3 and 4 mg of poly(rI) poly(rC) per kg died 24 to 48 h after drug administration. Only one cat per group was given the 3-or 4-mg dose of polynucleotides per kg because of expected toxicity. Of the inducers evaluated, poly(ICLC) and the mismatched analogs were tolerated best. Cats receiving up to 1 mg of each of the polynucleotides per kg did not experience central nervous system depression, although one of the cats receiving the mismatched analog did develop slight diarrhea. None ofthe cats receiving poly(ICLC) developed diarrhea, and the physical manifestation of toxicity appeared to be different. Poly(rI)-poly(rC) was tolerated up to 0.1 mg/kg, but cats that received a dose as low as 0.5 mg/kg developed diarrhea and slight central nervous system depression.
The interferon-inducing and toxicity data are summarized in Table 2 .
DISCUSSION
With the potential of interferon as an antineoplastic and antiviral agent, efforts have focused on developing methods ofutilizing the interferon system. One approach has been the development (17) . A comparison of pyrogenicity to interferon induction was not, however, made. In mice, the mismatched analog was nearly as active an antiviral agent as poly(rI) -poly(rC), but the only index of comparative toxicity followed was the 50% lethal dose (LD50) of each, where poly(rI) -poly[r(C12Uracil)n] was less toxic. In monkeys, poly(ICLC) induced high levels of circulating interferon and appeared to be about as well tolerated as poly(rI) -poly(rC) (9) . In initial clinical studies, poly(ICLC) induced high levels of circulating interferon, VOL. 17, 1980 on November 2, 2017 by guest http://aac.asm.org/ 992 STRINGFELLOW AND WEED higher than with poly(rI).poly(rC), and was nearly as well tolerated as poly(rI) *poly(rC) (8) . Further studies on the clinical toxicity and interferon response induced by poly(ICLC) are now under way, and results from these studies should give a better indication of toxicity.
Poly(rI) poly[r(C12Uracil)n] has not yet been evaluated clinically.
Although it is not know how predictive cats will be of tolerance and potency in humans, results from ongoing clinical trials may answer this question. The data in this report, however, indicate that it is possible to increase the antiviral efficacy of polynucleotides while not increasing the toxicity to the same extent. The results are also encouraging since poly(ICLC) induced high circulating levels of interferon in humans (8) and suggests that the use of interferon-inducing compounds is a viable approach to the development and utilization of the interferon system. LITERATURE CITED
